Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (1447)	9/19/2003 12:40:37 PM
From: Arthur Radley	Respond to of 1475

Wilder, I'm not embarassed, but I am "madder that heck" with Erik. It is obvious to me that he had a crystal ball in making "his" picks for 2003...even though technically I guess I'm not a part of the contest, but it still amazes me that I can't even get close to Erik's picks...with my meager 152% gain. When I get over my "huff" and we have the 2004 contest...rule number 1..Erik can't use a crystal ball!

To: keokalani'nui who wrote (1447)	9/19/2003 12:59:09 PM
From: Icebrg	Read Replies (1) \| Respond to of 1475

>>Ohh. If it's going private as part of a bankruptcy reorg then night cometh anon.>> I think they have already emerged from the administration. As you might remember that was just a ploy to prevent the Belgians from canceling the siplizumab license. That succeeded and the contract is still there. >>OT, are you at all embarrassed about the 2003 contest so far? >> Yes, I am. I just picked some of the shares in my portfolio that were really bombed-out. I was lucky(?) to avoid BTRN. And I was very lucky with my small cap. choices, as both COR and SPPI took a dive the last week of last year, providing an extra favorable starting point, but after that they have performed very well. Alexion is lagging behind for reasons you are well aware of. It will be interesting to see what they have to say to their defense at AHA. I didn't like the new issue, but the market seems already to have forgotten about that. They are extraordinary strong so far today. Medarex has been something of a disappointment. I think that the market has not yet appreciated the promise offered by anti-CTLA-4. The early malignant melanoma results were outstanding, but no-one seems yet to have noticed. Instead (some) people get excited over Genta and Genaense with their poor results. And that is a first-line treatment while MDX-010 was used as a second-line treatment. In real life I have sold Elan and Ligand, but still keep all the others. Erik